- New COVID variant CH.1.1 “Orthrus” has spreaded in 60 countries
- Current Drug Therapies for Non-Small Cell Lung Cancer
- Harvard study: studied healthy eating can prolong life and reduce risks of death!
- Massachusetts: Prisoners may get a reduced sentence by donating organs
- Smoking seriously hurts human brains
- Why are vegetarians more likely to suffer from depression than meat eaters?
Infection with ordinary coronavirus does not produce effective COVID-19 antibodies
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Latest research by British scientists: Infection with ordinary coronavirus does not produce effective COVID-19 antibodies.
British scientists published a paper in the latest issue of the journal “American Chemical Society Infectious Diseases” that their research showed that infection with two different common human coronaviruses does not produce antibodies that can effectively cross-react with the new coronavirus.
Therefore, previous infection with the common coronavirus is unlikely to combat or aggravate the new coronavirus infection.
Although the new coronavirus has swept the world, it is not the only coronavirus that can infect humans. However, unlike the new coronavirus, infection with the common human coronavirus (HCOV) usually has mild symptoms.
Because of the apparent genetic sequence similarity between the new coronavirus and its “closer relatives” of common human coronaviruses, the researchers wanted to figure out whether it was possible for the immune system to recognize the new coronavirus from a previous infection of common human coronaviruses.
If so, it may be possible to reactivate memory B cells, making them produce antibodies to help people fight the new coronavirus.
On the other hand, if antibodies against common human coronaviruses can recognize 2019-nCoV, but not enough to generate an immune response, it may lead to an antibody-dependent enhancement (ADE) effect – after virus infection, the antibodies produced are non-neutralizing or weakly neutralizing and action, such antibodies facilitate viral entry and infection of host cells, resulting in enhanced infectivity and virulence.
To this end, in the latest study, Tuomas Norris, professor of biophysics and biophysical chemistry at the University of Cambridge, and colleagues wanted to compare the detection of the strength and concentration of human common coronavirus and 2019-nCoV antibodies.
To do this, the research team used an analytical technique called “microfluidic antibody affinity”, which independently detects antibody affinity and concentration, unlike the traditionally used enzyme-linked immunosorbent assay (ELISA).
As a result, Norris et al. found that the serum of all patients who recovered from the new coronavirus contained a moderate number of antibodies with high affinity for the new coronavirus spike protein. In contrast, none of the serum collected before the outbreak of the novel coronavirus contained high-affinity antibodies to the novel coronavirus.
All 12 sera contained low amounts of high-affinity antibodies against two common human coronaviruses, indicating that the owners of the sera had previously been infected with common human coronaviruses. Other experiments showed that these antibodies did not bind to the new coronavirus.
The findings suggest that there is no significant cross-reactivity between antibodies against common human common coronaviruses and those against 2019-nCoV, the researchers said, so previous infection with common coronaviruses is unlikely to fight or aggravate 2019-nCoV infection.
(source:internet, reference only)